IL290482A - Salt and crystal forms of the activin receptor-like kinase inhibitor - Google Patents

Salt and crystal forms of the activin receptor-like kinase inhibitor

Info

Publication number
IL290482A
IL290482A IL290482A IL29048222A IL290482A IL 290482 A IL290482 A IL 290482A IL 290482 A IL290482 A IL 290482A IL 29048222 A IL29048222 A IL 29048222A IL 290482 A IL290482 A IL 290482A
Authority
IL
Israel
Prior art keywords
salt
kinase inhibitor
crystal forms
activin receptor
activin
Prior art date
Application number
IL290482A
Other languages
English (en)
Hebrew (he)
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of IL290482A publication Critical patent/IL290482A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL290482A 2019-08-13 2022-02-09 Salt and crystal forms of the activin receptor-like kinase inhibitor IL290482A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (1)

Publication Number Publication Date
IL290482A true IL290482A (en) 2022-04-01

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290482A IL290482A (en) 2019-08-13 2022-02-09 Salt and crystal forms of the activin receptor-like kinase inhibitor

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
TWI870440B (zh) 2025-01-21
KR20220052955A (ko) 2022-04-28
AU2020328534A1 (en) 2022-03-17
JP2022544272A (ja) 2022-10-17
JP2025148406A (ja) 2025-10-07
JOP20220014A1 (ar) 2023-01-30
MX2022001741A (es) 2022-03-11
US20220281879A1 (en) 2022-09-08
WO2021030386A1 (en) 2021-02-18
EP4013757A1 (en) 2022-06-22
CN114222745A (zh) 2022-03-22
AU2020328534B2 (en) 2026-04-30
UA130650C2 (uk) 2026-04-08
BR112022002597A2 (pt) 2022-07-05
CN119638704A (zh) 2025-03-18
JP7775186B2 (ja) 2025-11-25
TW202120509A (zh) 2021-06-01
CO2022001450A2 (es) 2022-05-31
CN114222745B (zh) 2025-03-25
MX2024014312A (es) 2024-12-06
KR102967623B1 (ko) 2026-05-21
CA3146701A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
ES3065954T3 (en) Fgfr inhibitors and methods of use thereof
ZA202005341B (en) Inhibitors of activin receptor-like kinase
IL287973A (en) acss2 inhibitors and methods of their use
ZA202407941B (en) Arginase inhibitors and methods of use thereof
EP3962484A4 (en) RAF KINASE INHIBITORS
IL279475A (en) Actonucleotidase inhibitors and methods of using them
JOP20220014A1 (ar) ملح وصور بلورية لمثبط كيناز شبيه بمستقبل أكتيفين
IL288903A (en) Indazoles and azaindazoles as lrrk2 repressors
IL280924A (en) Arginase inhibitors and methods of using them
IL326879A (en) Allosteric egfr inhibitors and methods of use thereof
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
ZA202105833B (en) Arginase inhibitors and methods of use thereof
IL286149A (en) Caspase inhibitors and methods of using them
HK40071240A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
IL277578A (en) New salt forms of URAT-1 inhibitors
HK40069053A (en) Kcnt1 inhibitors and methods of use
HK40045217A (zh) 激酶抑制剂化合物和组合物及使用方法
HK40070274A (en) Inhibitors of raf kinases
HK40064703A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40063536A (en) Acss2 inhibitors and methods of use thereof
HK40062239A (en) Acss2 inhibitors and methods of use thereof
HK40036932A (en) Nek inhibitors and methods of use
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof